FeesSafety
Pluang+

Goldman's GPIX ETF paid retirees $8,187 on $100K last year, outpacing Dividend Aristocrats' $2,020 income.

29 Oct 2026, 03:33 WIB
24/7 Wall Street
View Source
Bullish
Goldman's GPIX ETF paid retirees $8,187 on $100K last year, outpacing Dividend Aristocrats' $2,020 income.

Goldman's S&P 500 Premium Income ETF (GPIX) generated $8,187 in income on a $100,000 investment over the past year, paid monthly, compared to $2,020 from the Dividend Aristocrats ETF (NOBL) paid quarterly. Despite the higher income, GPIX's total returns closely matched NOBL's, which focuses on companies with long dividend growth histories. GPIX achieves income partly through selling options, offering higher current payouts but less predictable growth. Investors should choose based on whether they prioritize steady dividend growth or larger immediate income, and consider tax implications and return of capital in distributions.

Goldman's S&P 500 Premium Income ETF (GPIX) generated $8,187 in income on a $100,000 investment over the past year, providing a notable income figure for readers. For readers following US stocks, here is Pluang's market snapshot as of Oct 29, 2026 07:02 WIB: out of 150 priced US stocks tradable on Pluang, 84 rose and 66 fell today. Key movers include GSK at USD 48.81 (-4.18%), NU at USD 11.90 (-4.03%), and MU at USD 964.44 (+3.84%).

More News

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market is projected to grow from $5.8 billion in 2026 to $8.04 billion by 2032, at a CAGR of 5.54%. Growth is fueled by expanding chain cafes, specialty coffee methods like cold brew, and rising homegrown brands. However, rising coffee...

Market News
Neutral
1 hour ago
FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

HUTCHMED announced that the US FDA has granted orphan drug designation to sovleplenib for treating primary immune thrombocytopenia (ITP), a rare autoimmune disorder causing low platelet counts and bleeding risks. This status provides benefits like 7 ...

Market News
Bullish
1 hour ago
LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED held a global media test drive event at Chery's International Headquarters in Vu Hồ, featuring the luxury MPV LLounge and the high-performance Stormax SUV. Media representatives and influencers from UAE, Thailand, and Indonesia experienced a 1...

Market News
Bullish
1 hour ago
Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Kirby McInerney LLP is investigating NVE Corporation for possible violations of federal securities laws after the company reported a 47% revenue decline and a 33.7% stock price drop following its Q2 fiscal 2027 results. The revenue fall was attribute...

Market News
Bearish
3 hours ago
Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology received a notification from Nasdaq on October 13, 2026, stating it failed to meet the minimum bid price requirement of $1.00 per share over the past 30 days. The company has 180 days, until April 12, 2027, to restore its share price ...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App